Clinical outcomes
Myasthenia Gravis
MYASTHENIA GRAVIS, MYASTHENIA GRAVIS
MG‐specific clinical outcome measures (MG‐ADL, QMG, and MGC) showed that patients who received batoclimab had lower scores versus patients who received placebo during the double‐blind phase, although differences (change in mean [±SD]) were not statistically significant at the end of the double‐blind phase (6 weeks post‐baseline) (Fig. Clinical outcome measures over time. (A) MG‐ADL score; (B) QMG score; (C) MGC score; (D) MG‐QoL15r. MG, myasthenia gravis; MG‐ADL, MG Activities of Daily Living; MGC, Myasthenia Gravis Composite; MG‐QoL 15r, revised 15‐item Myasthenia Gravis Quality of Life; OLE, open‐label extension; q2w, once every 2 weeks; QMG, Quantitative Myasthenia Gravis; qw, once weekly; SD, standard deviation.